Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Retained Earnings: 2021-2024

  • ProQR Therapeutics N.V's Retained Earnings fell 5.84% to -$456.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$456.5 million, marking a year-over-year decrease of 5.84%. This contributed to the annual value of -$456.5 million for FY2024, which is 5.27% down from last year.
  • As of Q4 2024, ProQR Therapeutics N.V's Retained Earnings stood at -$456.5 million, which was down 5.84% from -$431.3 million recorded in Q4 2023.
  • In the past 5 years, ProQR Therapeutics N.V's Retained Earnings ranged from a high of -$363.5 million in Q4 2021 and a low of -$456.5 million during Q4 2024.
  • Moreover, its 3-year median value for Retained Earnings was -$431.3 million (2023), whereas its average is -$424.8 million.
  • Data for ProQR Therapeutics N.V's Retained Earnings shows a maximum YoY decreased of 11.51% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows ProQR Therapeutics N.V's Retained Earnings stood at -$363.5 million in 2021, then decreased by 6.40% to -$386.8 million in 2022, then declined by 11.51% to -$431.3 million in 2023, then fell by 5.84% to -$456.5 million in 2024.
  • Its Retained Earnings was -$456.5 million in Q4 2024, compared to -$431.3 million in Q4 2023 and -$386.8 million in Q4 2022.